Related Experiment Videos
Tracking atherosclerosis regression: a clinical tool in preventive cardiology
Allen Taylor1, Leslee J Shaw, Zahi Fayad
1Walter Reed Army Medical Center, Atlanta, GA, USA.
Atherosclerosis
|April 13, 2005
Summary
Quantitative coronary angiography initially assessed coronary artery disease progression. Advanced atherosclerosis imaging techniques now offer serial monitoring for evaluating preventive therapies and serve as surrogate endpoints in clinical trials.
Area of Science:
- Cardiovascular Medicine
- Medical Imaging
- Preventive Cardiology
Background:
- Coronary artery disease (CAD) progression was historically assessed by quantitative coronary angiography, linked to adverse cardiovascular outcomes.
- Emerging atherosclerosis imaging techniques provide new tools for evaluating preventive therapies by monitoring atherosclerosis burden.
- Large randomized trials for medical management of atherosclerosis are often impractical due to cost and resource constraints.
Purpose of the Study:
- To review the application of advanced atherosclerosis imaging modalities in cardiovascular prevention.
- To highlight their role as emerging tools for assessing therapeutic effectiveness and as surrogate endpoints in clinical trials.
Main Methods:
- Review of current literature on atherosclerosis imaging modalities.
- Focus on coronary computed tomography, carotid ultrasound, cardiovascular magnetic resonance imaging, and intravascular ultrasound.
- Evaluation of their capabilities for serial monitoring and use as intermediate endpoints.
Main Results:
- Atherosclerosis imaging modalities offer serial monitoring of atherosclerosis burden.
- These techniques serve as surrogate endpoints with substantial outcome relevance.
- They are increasingly used in clinical trials and individual patient management.
Conclusions:
- Advanced imaging techniques are valuable tools in cardiovascular prevention.
- They enable efficient evaluation of preventive therapies and facilitate clinical trial design.
- These modalities are transforming the management of atherosclerosis by providing objective measures of disease burden and treatment response.